Medtech: Assessing Potential Return On Investment
This article was originally published in Start Up
Medtech entrepreneurs and investors are awakening to a new reality in venture funding, where exit times are lengthening and returns on investment are falling short. At the recent IN3 meeting in Dublin, a panel of medtech investors discussed how they are adapting their investment strategies to this changing landscape.
You may also be interested in...
Dutch venture capital firm, Forbion Capital Partners, has launched a new €92 milion ($116 million) life science fund to invest in 12 to 15 new companies. This is first close for the new fund called Forbion Capital Fund III, en route to a target of €150 to €200 million.
According to a panel of strategic investors speaking at a recent IN3 meeting, structured deals that can help manage risk for medtech start-ups seeking funding and strategics looking for growth opportunities are on the rise.
The last five years have been brutal ones for medical device VCs and entrepreneurs, yet there’s still cause for hope. In a series of interviews, we asked venture capitalists, entrepreneurs, and executives: what gives you hope and what makes you optimistic about the future of medtech?